252 related articles for article (PubMed ID: 2769330)
41. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
42. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Noh SH; Yoo CH; Chung HC; Roh JK; Shin DW; Min JS
Oncology; 2001; 60(1):24-30. PubMed ID: 11150904
[TBL] [Abstract][Full Text] [Related]
43. The treatment of advanced gastric cancer.
Wils J
Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer].
Yabusaki H; Nashimoto A; Tanaka O
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1933-40. PubMed ID: 14650962
[TBL] [Abstract][Full Text] [Related]
45. [A case of gastric carcinoma remarkably responding to etoposide, adriamycin and cisplatin (EAP) therapy].
Nakamura Y; Hamada H; Yoshinobu H; Mori N; Nakajima I; Kurooka K; Tanaka A; Nakamura T; Yasutomi M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2995-8. PubMed ID: 3178244
[TBL] [Abstract][Full Text] [Related]
46. Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Hayakawa M; Morise K; Chin K; Sugihara M; Morooka Y; Maeda H; Hattori T; Saito H
Jpn J Clin Oncol; 1994 Oct; 24(5):282-8. PubMed ID: 7967107
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study.
Clark JL; Küçük O; Neuberg DS; Benson AB; Taylor SG; Pandya KJ; Mansour EG; Douglass HO; Haller DG
Am J Clin Oncol; 1995 Aug; 18(4):318-24. PubMed ID: 7625373
[TBL] [Abstract][Full Text] [Related]
48. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
[TBL] [Abstract][Full Text] [Related]
50. [Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Kondo K; Murase M; Yokoyama Y; Kato J; Hibi K; Kasai Y; Akiyama S; Ito K; Takagi H
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1299-303. PubMed ID: 8831742
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
[TBL] [Abstract][Full Text] [Related]
53. Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen.
Chung HC; Roh JK; Park YJ; Lee SI; Min JS; Lee JT; Lee KB; Kim BS
Yonsei Med J; 1990 Mar; 31(1):74-9. PubMed ID: 2346043
[TBL] [Abstract][Full Text] [Related]
54. The effectiveness of a combination of etoposide/adriamycin/cisplatin (EAP) against inoperable gastric cancer--report of a histologically proven case.
Tahara H; Ogawa M; Kido Y; Shiozaki H; Ohashi I; Mori T; Sakurai M
Jpn J Surg; 1991 Jul; 21(4):433-7. PubMed ID: 1960901
[TBL] [Abstract][Full Text] [Related]
55. [Neoadjuvant chemotherapy for locally advanced gastric cancer].
Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E
Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621
[TBL] [Abstract][Full Text] [Related]
56. [Effect of high dose etoposide, adriamycin, cisplatin (EAP) therapy with autologous bone marrow transplantation in gastric cancer].
Suzuki T; Ochiai T; Ozaki M; Asano T; Koide Y; Gunji Y; Shu S; Hori S; Nabeya Y; Isono K
Gan To Kagaku Ryoho; 1990 May; 17(5):1069-72. PubMed ID: 2334173
[TBL] [Abstract][Full Text] [Related]
57. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
[TBL] [Abstract][Full Text] [Related]
58. [A case of complete remission in brain metastasis from lung adenocarcinoma with EAP (etoposide, adriamycin, cisplatin)].
Matsumoto S; Yoshimoto A; Ohsaki A; Murashima N; Ishii Y; Seno N
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1933-6. PubMed ID: 2393312
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
